Thailandhas proved that a well-fund, politically-supported public policy could be effective in preventing the spread of HIV/AIDS on a national scale. It is currently facing increased pressure to accept higher standards of intellectual property (IP) protection (the so-called TRIPS-Plus) under bilateral free trade agreements (FTA) proposed by theUnited States. The proposed US FTA threatens to restrict the measures the country can take to pursue affordable drugs, and will affect ability of Thailandto continue its successful ARV treatment and other healthcare programmes. The paper argues that the TRIPS-Plus regime generates a negative impact on poor people's access to medicines, and the ARV treatment programme inThailandis presented as an illustrative example. 
Introduction
Anti-retroviral (ARV) drugs have the potential to dramatically improve the health and extend the lives of many people living with HIV/AIDS (PLWHA). However, the high price of these drugs put them out of reach of the vast majority of PLWHA in many developing countries. The problem is acute for example in Thailand, where HIV infection levels are high and public financial resources are limited. The importance of pharmaceutical pricing has become more crucial since the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS), which is part of the World
Trade Organisation (WTO) multilateral agreements, requires all member states, including developing countries, to provide patent protection for pharmaceuticals and effectively enforce patent rights. In addition, the developing countries are now facing increased pressure toward higher standards of intellectual property (IP) protection (the so-called TRIPS-Plus), which appears in the form of bilateral free trade agreements (FTA).
Such high-level IP standards may be inappropriate for developing countries and would restrict access to essential medicines to fight HIV/AIDS and other pandemics.
The fundamental question that faces the pharmaceutical world today is how best to provide drugs to the general population and how to do so cheaply. This note reviews some major issues relating to the controversial TRIPS-Plus rules under various FTAs that pose many challenges to the developing countries. The paper argues that the TRIPS-Plus regime generates a negative impact on poor people's access to medicines in general, and the ARV treatment programme in Thailand is presented as an illustrative example.
Access to Medicines: Legal and Moral Rights

i. Restricting access to medicine -violation of human rights
The right to health has been recognized as a fundamental human rights. It is enshrined in a number of treaties, including the Constitution of the World Health Organization (WHO), the United Nations Charter (Arts. 1, 55 and 56), the Universal Declaration on
Human rights (Art.25), and the Convention on the Rights of the Child (Art.24). The most important human rights instrument that explicitly recognizes the right to health is the International Covenant on Economic, Social and Cultural Rights (ICESCR).
Article 12 of the ICESCR creates a legally binding right to health on the State, and
Article 2 imposes legal obligations on all State parties to co-operate internationally to realize this right.
The right to health was defined as "a right to the enjoyment of a variety of facilities, goods, services and conditions necessary for the realization of the highest attainable standard of health." which includes "a system of urgent medical care in cases of accidents, epidemics and similar health hazards," as well as "the provision of essential Thailand has to ensure that its law and policy will be supportive of public health policies which promote broad access to safe, effective and affordable medicines. The breach of state power by the introduction of the TRIPS-Plus rules under an FTA that would undermine Thailand's substantive ability to deal with public health problems is clearly a violation of the right to health of the Thai population, which is not only the constitutional right but also a legally-binding human rights obligation of Thailand.
iii. The right to health and access to medicine under patent law
The right to health is safeguard by various mechanisms, including those under the patent legislation. While the first patent law of Thailand, the Patent Act B.E. 2522, provides protection and exclusivity over pharmaceuticals, it ensures that the essential products will meet a domestic demand at reasonable and affordable prices by incorporating some possible legal measures to combat abusive practices and enforce local working of patents. The mechanisms include compulsory licensing and parallel import.
The system of compulsory licensing is envisaged as a mechanism to improve free competition, and to authorize the use of patented article for public interest. A compulsory license may be granted to a private competitor or a State agency to use patented substances for meeting public needs. Both in the legal and economic context, it could make a compelling case for the grant of such license, or at least for threatening to do so should the patent holder not lower the prices of its products.
Although the mechanism is important and can be used to enhance access to medicines, there are still practical difficulties in applying those provisions due to the incongruity of the Thai legal system and political pressure coming from the West.
In December 1999 a group of PLWHA and NGOs staged a massive demonstration outside the the Ministry of Public Health demanding the use of compulsory licensing of one important patented ARV drug, ddI (see further below). But this was not accepted by the Thai government which faced a great deal of hostility and threats from the United States government (Kuanpoth 2002: 344-345) . Just as everywhere, political factors play an important part in the use of compulsory licensing in Thailand.
One factor to reckon with seems to be the lack of political will by the Thai government to actually invoke the scheme of compulsory licensing in the public interest.
The incorporation of the international exhaustion doctrine 1 and the large variation in drug prices in the world market has led to the evolution of a marketing practice, called "parallel importing", in which drugs sold in a country with low prices are exported to another country where prices are high at lower prices. While the pharmaceutical company tends to use legal rights under patents and other IP rights as territorial restrictions to enhance revenue, developing countries may adopt a policy of encouraging parallel import of foreign-made drugs in order to lower the price level of drugs in their local market (Maskus 2000) . The possibility for the entry of foreign drugs into the domestic market will confront the licensed distributors with competitive pressure in setting prices (Abbott 1998; Beal 1998) .
In Thailand the principle of international exhaustion was incorporated into the patent law in 1999 in order to permit parallel importing of patented articles. While in principle compulsory licensing and parallel imports could enhance access to medicines, the use of these two mechanisms would be restricted by the introduction of TRIPS-Plus rules under an FTA that Thailand is negotiating with the US. Women often face a disproportionate burden caring for sick family members or younger siblings, restricting their job or education opportunities. In many cases girls are much more likely to be withdrawn from school to perform caring tasks.
HIV/AIDS and ARV Treatment Programme in Thailand
ii. The Thai treatment programme against HIV/AIDS a) Preventive programme
Thailand's initial efforts in tackling HIV/AIDS have proved remarkably successful (Piot 2001 (Piot : 1106 (Piot -1112 . Comprehensive prevention campaigns adopted by the Thai government in the 1990s were the main factor that slowed down the rate of HIV infections. In response to AIDS epidemic in the early 1990s, the Thai government There are approximately more than one million immigrants working illegally in
Thailand. Most migrant workers are from Cambodia, Laos and Myanmar, who cross over the border in search of work and trading opportunities. Among these, there are girls and women drawn into the commercial sex industry, and those foreign sex workers are at significant risk of contracting the disease from their sexual activities.
HIV prevalence among these women is likely to be higher than among their Thai counterparts. While the Thai government healthcare system is already serving the health needs of the local people, these illegal immigrants do not have access to health and other social services in Thailand and miss out on the ARV treatment programme. 
International Trade Regulation and Its Impacts on Access to Medicines
i. TRIPS, the Doha Declaration and access to medicines
The ii.
The proposed Thai-US free trade agreement and TRIPS-Plus rules
The early 2000s saw the proliferation of FTA, which arose after some WTO Member countries became impatient with slow progress in multilateral trade negotiations.
Since trade liberalization was getting more difficult under the WTO framework, some developed country governments, particularly the US government, have used bilateral and regional trade fora to achieve what they could not in the multilateral WTO forum (enforcing inflexible high level IP protection in developing countries). They concern all areas of IP such as patents, trademarks and copyright. On patents,
TRIPS-Plus rules generally contain:
• Inclusion of new areas of IP (e.g. patenting of life forms, data exclusivity);
• Implementation of a more extensive IP standard (e.g. extension of patent and copyright terms);
• Limiting flexibilities that countries have under TRIPS (e.g. restricting the right of governments to allow the production, marketing, and import of generic medicines);
• Requiring the parties to the FTA to ratify or accede to a host of WIPO treaties (e.g. the Patent Cooperation Treaty, the UPOV Convention, WIPO internet treaties). In the case of public non-commercial use, national emergency or other circumstances of extreme urgency, the USTR text provided that a compulsory license can be granted only in accordance with these conditions:
• A compulsory license can be issued only to the public sector or third parties authorised by the government.
• The patent holder shall receive full compensation under the TRIPS provision for compulsory licensing.
• There must be no requirement for the transfer of undisclosed information or for the disclosure of know-how without the consent of the right holder.
The constraints which might be imposed on Thailand threaten to restrict the measures it can take to pursue affordable drugs. The USTR text prohibits Thailand from allowing pre-grant opposition to a patent. The effectiveness of the patent system primarily depends on the quality of the technical examination. In developed countries, it is not uncommon to find a number of invalid patents being issued each year (Sherwoon et al 1999) . In view of the weaker patent examination system, it is thus logical to assume that the number of invalid patents granted in the developing countries like Thailand is even higher (Tanasugarn 1999 ).
The case of ddI discussed earlier reflects the policy significance of the pre-grant opposition procedure which permits the invalidation or amendment of patents before the patent office examination. A straightforward administrative procedure is necessary because it allows the patentee's competitors to challenge the validity of the patent at relatively low cost prior to an infringement action. The system also reduces the excessive burden on the court and contributes to speedy proceedings of patent invalidation.
The US text also prevents Thailand from revoking patents on grounds other than those that would have justified a refusal to grant the patent (e.g. lack of patentability, insufficiency of or unauthorised amendments to the patent specification, non- give no thought to HIV-infected patients in developing countries who need the medicines most direly. Those companies are pursuing the higher level of protection not to increase research and development, but to limit generic competition in order to increase their profits.
Thailand unquestionably possesses the manufacturing capacity to produce the generic ARVs. Such capacity will allow Thailand to take advantage of the TRIPS flexibilities to get affordable treatment for its growing HIV/AIDS population. However the constraints under the proposed US FTA threaten to restrict the measures the country can take to pursue affordable drugs, and will affect ability of Thailand to continue its ARV treatment and other healthcare programmes. Thailand must be aware that it has obligation to ensure the realization of the right to health, which means any increase in IP protection must be balanced by the right of access to healthcare and essential medicines. In order to make ARV treatment affordable for the most vulnerable groups in the country and comply with the right to health under the international human rights instruments that Thailand adheres, generic competition must be upheld and the Thai government must reject the TRIPS-Plus rules proposed by the US.
The author is also thankful to Professor Sol Picciotto, Lancaster University Law School, whose comments greatly improved this manuscript. 1 When the patented drug has been sold by the right holder or with his consent, the patent holder cannot prohibit the subsequent import or resale of the product because his rights to the product have been exhausted by the act of selling it. This is known as "the principle of exhaustion of rights". Countries may implement this principle differently. Some may apply the principle when drugs are sold within the national border only (called national exhaustion), but other countries, notably the European Union, allow no restrictions on import when drugs are put on sale in members of the community (called regional exhaustion). Many countries currently adopt the principle of international exhaustion of rights, whereby the patent rights are exhausted after the first marketing of the patented article by the right holder or with his consent, regardless of the place of marketing.
